<s id="wsj_2007.1"> 24
3 	 0 	 N/N 	 1 	 companies Three
3 	 1 	 N/N 	 1 	 companies leading
3 	 2 	 N/N 	 1 	 companies drug
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 companies reported
7 	 4 	 (S[dcl]\NP)/NP 	 2 	 earnings reported
7 	 5 	 N/N 	 1 	 earnings robust
7 	 6 	 N/N 	 1 	 earnings third-quarter
7 	 9 	 S[pss]\NP 	 1 	 earnings bolstered <XB>
9 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 bolstered by
12 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 sales by
12 	 11 	 N/N 	 1 	 sales strong
12 	 13 	 (NP\NP)/NP 	 1 	 sales of
18 	 13 	 (NP\NP)/NP 	 2 	 drugs of
18 	 14 	 N/N 	 1 	 drugs newer
18 	 16 	 N/N 	 1 	 drugs big-selling
18 	 17 	 N/N 	 1 	 drugs prescriptions
18 	 19 	 (NP\NP)/(S[dcl]\NP) 	 1 	 drugs that
18 	 20 	 (S[dcl]\NP)/NP 	 1 	 drugs provide <XB>
20 	 19 	 (NP\NP)/(S[dcl]\NP) 	 2 	 provide that
23 	 20 	 (S[dcl]\NP)/NP 	 2 	 margins provide
23 	 21 	 N/N 	 1 	 margins hefty
23 	 22 	 N/N 	 1 	 margins profit
<\s>
<s id="wsj_2007.2"> 29
2 	 0 	 N/N 	 1 	 Co. Merck
2 	 1 	 N/N 	 1 	 Co. &
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 Co. reported
6 	 5 	 (N/N)/(N/N) 	 2 	 % 25
7 	 3 	 (S[dcl]\NP)/NP 	 2 	 increase reported
7 	 4 	 NP[nb]/N 	 1 	 increase a
7 	 6 	 N/N 	 1 	 increase %
7 	 8 	 (NP\NP)/NP 	 1 	 increase in
9 	 8 	 (NP\NP)/NP 	 2 	 earnings in
12 	 11 	 N/N 	 1 	 Co. Warner-Lambert
12 	 13 	 (NP[nb]/N)\NP 	 2 	 Co. 's
14 	 13 	 (NP[nb]/N)\NP 	 1 	 profit 's
14 	 15 	 S[dcl]\NP 	 1 	 profit rose
15 	 17 	 (S\NP)\(S\NP) 	 2 	 rose %
17 	 16 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 22
22 	 19 	 N/N 	 1 	 Co. Eli
22 	 20 	 N/N 	 1 	 Co. Lilly
22 	 21 	 N/N 	 1 	 Co. &
22 	 23 	 (NP[nb]/N)\NP 	 2 	 Co. 's
25 	 23 	 (NP[nb]/N)\NP 	 1 	 income 's
25 	 24 	 N/N 	 1 	 income net
25 	 26 	 S[dcl]\NP 	 1 	 income rose
26 	 28 	 (S\NP)\(S\NP) 	 2 	 rose %
28 	 27 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 24
<\s>
<s id="wsj_2007.3"> 9
1 	 0 	 NP[nb]/N 	 1 	 results The
1 	 2 	 (S[dcl]\NP)/PP 	 1 	 results were
3 	 2 	 (S[dcl]\NP)/PP 	 2 	 in were
4 	 3 	 PP/NP 	 1 	 line in
4 	 5 	 (NP\NP)/NP 	 1 	 line with
6 	 7 	 (NP[nb]/N)\NP 	 2 	 analysts '
8 	 5 	 (NP\NP)/NP 	 2 	 expectations with
8 	 7 	 (NP[nb]/N)\NP 	 1 	 expectations '
<\s>
<s id="wsj_2007.4"> 3
2 	 0 	 N/N 	 1 	 Co Merck
2 	 1 	 N/N 	 1 	 Co &
<\s>
<s id="wsj_2007.5"> 23
0 	 2 	 NP\NP 	 1 	 Merck Rahway
0 	 4 	 NP\NP 	 1 	 Merck N.J. <XU>
0 	 6 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Merck continued
0 	 8 	 (S[b]\NP)/NP 	 1 	 Merck lead <XB>
7 	 6 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to continued
8 	 7 	 (S[to]\NP)/(S[b]\NP) 	 2 	 lead to
8 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 lead with
10 	 8 	 (S[b]\NP)/NP 	 2 	 industry lead
10 	 9 	 NP[nb]/N 	 1 	 industry the
15 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 performance with
15 	 12 	 NP[nb]/N 	 1 	 performance a
15 	 13 	 N/N 	 1 	 performance strong
15 	 14 	 N/N 	 1 	 performance sales
15 	 16 	 (NP\NP)/NP 	 1 	 performance in
18 	 16 	 (NP\NP)/NP 	 2 	 human in
18 	 17 	 NP[nb]/N 	 1 	 human the
22 	 16 	 (NP\NP)/NP 	 2 	 segment in
22 	 17 	 NP[nb]/N 	 1 	 segment the
22 	 20 	 N/N 	 1 	 segment animal
22 	 21 	 N/N 	 1 	 segment health-products
<\s>
<s id="wsj_2007.6"> 17
3 	 0 	 NP[nb]/N 	 1 	 dollar A
3 	 1 	 N/N 	 1 	 dollar stronger
3 	 2 	 N/N 	 1 	 dollar U.S.
3 	 4 	 (S[dcl]\NP)/NP 	 1 	 dollar reduced
4 	 11 	 (S\NP)\(S\NP) 	 2 	 reduced %
4 	 14 	 (S\NP)\(S\NP) 	 2 	 reduced % <XU>
9 	 4 	 (S[dcl]\NP)/NP 	 2 	 growth reduced
9 	 5 	 N/N 	 1 	 growth third-quarter
9 	 7 	 N/N 	 1 	 growth first-nine-month
9 	 8 	 N/N 	 1 	 growth sales
11 	 10 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 2
11 	 16 	 ((S\NP)\(S\NP))\((S\NP)\(S\NP)) 	 3 	 % respectively
14 	 13 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 3
14 	 16 	 ((S\NP)\(S\NP))\((S\NP)\(S\NP)) 	 3 	 % respectively
<\s>
<s id="wsj_2007.7"> 22
1 	 0 	 N/N 	 1 	 sales International
1 	 2 	 (S[dcl]\NP)/PP 	 1 	 sales accounted
2 	 15 	 ((S\NP)\(S\NP))/PP 	 2 	 accounted compared
3 	 2 	 (S[dcl]\NP)/PP 	 2 	 for accounted
5 	 3 	 PP/NP 	 1 	 % for
5 	 4 	 N/N 	 1 	 % 47
5 	 6 	 (NP\NP)/NP 	 1 	 % of
9 	 6 	 (NP\NP)/NP 	 2 	 sales of
9 	 7 	 N/N 	 1 	 sales total
9 	 8 	 N/N 	 1 	 sales company
9 	 10 	 (NP\NP)/NP 	 1 	 sales for
13 	 10 	 (NP\NP)/NP 	 2 	 months for
13 	 11 	 NP[nb]/N 	 1 	 months the
13 	 12 	 N/N 	 1 	 months nine
16 	 15 	 ((S\NP)\(S\NP))/PP 	 3 	 with compared
16 	 21 	 (PP\PP)\NP 	 1 	 with earlier
18 	 16 	 PP/NP 	 1 	 % with
18 	 17 	 N/N 	 1 	 % 50
20 	 19 	 NP[nb]/N 	 1 	 year a
20 	 21 	 (PP\PP)\NP 	 2 	 year earlier
<\s>
<s id="wsj_2007.8"> 13
0 	 1 	 (NP\NP)/NP 	 1 	 Sales for
0 	 4 	 S[dcl]\NP 	 1 	 Sales rose
3 	 1 	 (NP\NP)/NP 	 2 	 quarter for
3 	 2 	 NP[nb]/N 	 1 	 quarter the
4 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
4 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 rose from
6 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
8 	 6 	 N/N[num] 	 1 	 billion $
8 	 7 	 N/N 	 1 	 billion 1.63
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
12 	 10 	 N/N[num] 	 1 	 billion $
12 	 11 	 N/N 	 1 	 billion 1.47
<\s>
<s id="wsj_2007.9"> 31
0 	 8 	 (S[dcl]\NP)/NP 	 1 	 Mevacor had
2 	 3 	 (NP[nb]/N)\NP 	 2 	 Merck 's
6 	 3 	 (NP[nb]/N)\NP 	 1 	 drug 's
6 	 4 	 N/N 	 1 	 drug new
6 	 5 	 N/N 	 1 	 drug cholesterol-lowering
6 	 8 	 (S[dcl]\NP)/NP 	 1 	 drug had
8 	 30 	 (S[dcl]\S[dcl])\NP 	 1 	 had said
10 	 8 	 (S[dcl]\NP)/NP 	 2 	 sales had
10 	 9 	 N/N 	 1 	 sales higher
10 	 11 	 (NP\NP)/S[dcl] 	 1 	 sales than
15 	 12 	 NP[nb]/N 	 1 	 medicine any
15 	 13 	 N/N 	 1 	 medicine other
15 	 14 	 N/N 	 1 	 medicine prescription
15 	 16 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 medicine has
15 	 18 	 S[pt]\NP 	 1 	 medicine achieved <XB>
16 	 11 	 (NP\NP)/S[dcl] 	 2 	 has than
16 	 17 	 (S\NP)\(S\NP) 	 2 	 has ever
18 	 16 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 achieved has
18 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 achieved in
18 	 22 	 ((S\NP)\(S\NP))/NP 	 2 	 achieved in
21 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 U.S. in
21 	 20 	 NP[nb]/N 	 1 	 U.S. the
24 	 22 	 ((S\NP)\(S\NP))/NP 	 3 	 year in
24 	 23 	 NP[nb]/N 	 1 	 year the
24 	 25 	 (NP\NP)/NP 	 1 	 year following
26 	 25 	 (NP\NP)/NP 	 2 	 introduction following
29 	 28 	 NP[nb]/N 	 1 	 company the
29 	 30 	 (S[dcl]\S[dcl])\NP 	 2 	 company said
<\s>
<s id="wsj_2007.10"> 9
1 	 0 	 NP[nb]/N 	 1 	 drug The
1 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 drug was
1 	 3 	 S[pss]\NP 	 1 	 drug introduced <XB>
3 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 introduced was
3 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 introduced in
3 	 7 	 ((S\NP)\(S\NP))/N 	 2 	 introduced this
6 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 Germany in
6 	 5 	 N/N 	 1 	 Germany West
8 	 7 	 ((S\NP)\(S\NP))/N 	 3 	 year this
<\s>
<s id="wsj_2007.11"> 26
1 	 0 	 N/N 	 1 	 competition Intense
1 	 5 	 S[dcl]\NP 	 1 	 competition led
5 	 3 	 (S\NP)/(S\NP) 	 2 	 led however
5 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 led to
9 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 declines to
9 	 7 	 N/N 	 1 	 declines unit
9 	 8 	 N/N 	 1 	 declines sales
9 	 10 	 (NP\NP)/NP 	 1 	 declines for
12 	 10 	 (NP\NP)/NP 	 2 	 group for
12 	 11 	 NP[nb]/N 	 1 	 group a
12 	 13 	 (NP\NP)/NP 	 1 	 group of
12 	 22 	 (NP\NP)/NP 	 1 	 group including
14 	 15 	 (NP[nb]/N)\NP 	 2 	 Merck 's
20 	 13 	 (NP\NP)/NP 	 2 	 products of
20 	 15 	 (NP[nb]/N)\NP 	 1 	 products 's
20 	 16 	 N/N 	 1 	 products established
20 	 17 	 N/N 	 1 	 products human
20 	 19 	 N/N 	 1 	 products animal-health
23 	 22 	 (NP\NP)/NP 	 2 	 Aldomet including
25 	 22 	 (NP\NP)/NP 	 2 	 Indocin including
<\s>
<s id="wsj_2007.12"> 19
6 	 0 	 (S/S)/NP 	 2 	 trading In
6 	 1 	 N/N 	 1 	 trading New
6 	 2 	 N/N 	 1 	 trading York
6 	 3 	 N/N 	 1 	 trading Stock
6 	 4 	 N/N 	 1 	 trading Exchange
6 	 5 	 N/N 	 1 	 trading composite
10 	 9 	 N/N 	 1 	 shares Merck
10 	 11 	 (S[dcl]\NP)/PP 	 1 	 shares closed
11 	 0 	 (S/S)/NP 	 1 	 closed In
11 	 7 	 S/S 	 1 	 closed yesterday
11 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 closed up
12 	 11 	 (S[dcl]\NP)/PP 	 2 	 at closed
13 	 12 	 PP/NP 	 1 	 $ at
14 	 13 	 N/N[num] 	 1 	 75.25 $
18 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 cents up
18 	 17 	 N/N 	 1 	 cents 50
<\s>
<s id="wsj_2007.13"> 2
1 	 0 	 N/N 	 1 	 Co Warner-Lambert
<\s>
<s id="wsj_2007.14"> 31
0 	 7 	 (S[dcl]\NP)/NP 	 1 	 Warner-Lambert reported
3 	 2 	 N/N 	 1 	 Plains Morris
3 	 7 	 (S[dcl]\NP)/NP 	 1 	 Plains reported
5 	 7 	 (S[dcl]\NP)/NP 	 1 	 N.J. reported
8 	 7 	 (S[dcl]\NP)/NP 	 2 	 sales reported
8 	 9 	 (NP\NP)/(S[dcl]\NP) 	 1 	 sales that
8 	 10 	 (S[dcl]\NP)/NP 	 1 	 sales were <XB>
10 	 9 	 (NP\NP)/(S[dcl]\NP) 	 2 	 were that
12 	 10 	 (S[dcl]\NP)/NP 	 2 	 record were
12 	 11 	 NP[nb]/N 	 1 	 record a
12 	 13 	 (NP\NP)/NP 	 1 	 record for
15 	 13 	 (NP\NP)/NP 	 2 	 quarter for
15 	 14 	 NP[nb]/N 	 1 	 quarter any
19 	 10 	 (S[dcl]\NP)/NP 	 2 	 quarter were
19 	 17 	 NP[nb]/N 	 1 	 quarter the
19 	 18 	 N/N 	 1 	 quarter eighth
19 	 20 	 (NP\NP)/NP 	 1 	 quarter in
19 	 23 	 (NP\NP)/NP 	 1 	 quarter of
22 	 20 	 (NP\NP)/NP 	 2 	 row in
22 	 21 	 NP[nb]/N 	 1 	 row a
30 	 23 	 (NP\NP)/NP 	 2 	 growth of
30 	 24 	 NP/NP 	 1 	 growth 20
30 	 25 	 NP[nb]/N 	 1 	 growth % <XU>
30 	 27 	 NP[nb]/N 	 1 	 growth more
30 	 28 	 N/N 	 1 	 growth per-share
30 	 29 	 N/N 	 1 	 growth earnings
<\s>
<s id="wsj_2007.15"> 39
0 	 1 	 ((S\NP)\(S\NP))/NP 	 2 	 Spurred by
2 	 1 	 ((S\NP)\(S\NP))/NP 	 3 	 growth by
2 	 3 	 (NP\NP)/NP 	 1 	 growth in
5 	 3 	 (NP\NP)/NP 	 2 	 sales in
5 	 4 	 N/N 	 1 	 sales world-wide
5 	 6 	 (NP\NP)/NP 	 1 	 sales of
8 	 7 	 NP[nb]/N 	 1 	 company the
8 	 9 	 (NP[nb]/N)\NP 	 2 	 company 's
11 	 6 	 (NP\NP)/NP 	 2 	 drugs of
11 	 9 	 (NP[nb]/N)\NP 	 1 	 drugs 's
11 	 10 	 N/N 	 1 	 drugs prescription
13 	 14 	 (S[dcl]\NP)/S[dcl] 	 1 	 Warner-Lambert said
15 	 16 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 1989 will
15 	 17 	 (S[b]\NP)/NP 	 1 	 1989 be <XB>
16 	 14 	 (S[dcl]\NP)/S[dcl] 	 2 	 will said
17 	 16 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be will
17 	 25 	 (((S\NP)\(S\NP))/(S[pt]\NP))/NP 	 2 	 be with
20 	 17 	 (S[b]\NP)/NP 	 2 	 year be
20 	 18 	 NP[nb]/N 	 1 	 year the
20 	 19 	 N/N 	 1 	 year best
20 	 21 	 (NP\NP)/NP 	 1 	 year in
23 	 21 	 (NP\NP)/NP 	 2 	 history in
23 	 22 	 NP[nb]/N 	 1 	 history its
27 	 25 	 (((S\NP)\(S\NP))/(S[pt]\NP))/NP 	 4 	 earnings with
27 	 26 	 N/N 	 1 	 earnings per-share
27 	 28 	 (S[pt]\NP)/(S[to]\NP) 	 1 	 earnings expected <XB>
27 	 30 	 (S[b]\NP)/NP 	 1 	 earnings increase <XB>
28 	 25 	 (((S\NP)\(S\NP))/(S[pt]\NP))/NP 	 3 	 expected with
29 	 28 	 (S[pt]\NP)/(S[to]\NP) 	 2 	 to expected
30 	 29 	 (S[to]\NP)/(S[b]\NP) 	 2 	 increase to
30 	 35 	 ((S\NP)\(S\NP))/NP 	 2 	 increase to
31 	 32 	 ((N/N)/(N/N))\(S[adj]\NP) 	 3 	 more than
33 	 32 	 ((N/N)/(N/N))\(S[adj]\NP) 	 2 	 20 than
34 	 30 	 (S[b]\NP)/NP 	 2 	 % increase
34 	 33 	 N/N 	 1 	 % 20
37 	 35 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
37 	 36 	 N/N 	 1 	 $ about
38 	 37 	 N/N[num] 	 1 	 6.10 $
<\s>
<s id="wsj_2007.16"> 13
0 	 1 	 (NP\NP)/NP 	 1 	 Sales for
0 	 4 	 S[dcl]\NP 	 1 	 Sales rose
3 	 1 	 (NP\NP)/NP 	 2 	 quarter for
3 	 2 	 NP[nb]/N 	 1 	 quarter the
4 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
4 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 rose from
6 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
8 	 6 	 N/N[num] 	 1 	 billion $
8 	 7 	 N/N 	 1 	 billion 1.11
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
12 	 10 	 N/N[num] 	 1 	 billion $
12 	 11 	 N/N 	 1 	 billion 1.03
<\s>
<s id="wsj_2007.17"> 19
2 	 0 	 N/N 	 1 	 sales Prescription-drug
2 	 1 	 N/N 	 1 	 sales world-wide
2 	 3 	 S[dcl]\NP 	 1 	 sales rose
3 	 5 	 (S\NP)\(S\NP) 	 2 	 rose %
3 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 rose in
3 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
5 	 4 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 9
8 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 quarter in
8 	 7 	 NP[nb]/N 	 1 	 quarter the
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
12 	 10 	 N/N[num] 	 1 	 million $
12 	 11 	 N/N 	 1 	 million 340
15 	 14 	 N/N 	 1 	 sales U.S.
15 	 16 	 S[dcl]\NP 	 1 	 sales rose
16 	 18 	 (S\NP)\(S\NP) 	 2 	 rose %
18 	 17 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 15
<\s>
<s id="wsj_2007.18"> 25
1 	 0 	 NP[nb]/N 	 1 	 segment The
1 	 2 	 (NP[nb]/N)\NP 	 2 	 segment 's
3 	 2 	 (NP[nb]/N)\NP 	 1 	 growth 's
3 	 4 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 growth was
3 	 5 	 S[pss]\NP 	 1 	 growth led <XB>
5 	 4 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 led was
5 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 led by
7 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 sales by
7 	 8 	 (NP\NP)/NP 	 1 	 sales of
11 	 8 	 (NP\NP)/NP 	 2 	 drugs of
11 	 9 	 NP[nb]/N 	 1 	 drugs the
11 	 10 	 N/N 	 1 	 drugs cardiovascular
11 	 12 	 NP\NP 	 1 	 drugs Lopid
11 	 14 	 (NP\NP)/N 	 1 	 drugs a <XU>
11 	 19 	 NP\NP 	 1 	 drugs Dilzem <XU>
11 	 21 	 (NP\NP)/N 	 1 	 drugs a <XU>
16 	 14 	 (NP\NP)/N 	 2 	 regulator a
16 	 15 	 N/N 	 1 	 regulator lipid
24 	 21 	 (NP\NP)/N 	 2 	 blocker a
24 	 22 	 N/N 	 1 	 blocker calcium
24 	 23 	 N/N 	 1 	 blocker channel
<\s>
<s id="wsj_2007.19"> 40
1 	 0 	 N/N 	 1 	 sales World-wide
1 	 2 	 (NP\NP)/NP 	 1 	 sales of
1 	 23 	 S[dcl]\NP 	 1 	 sales increased
3 	 4 	 (NP[nb]/N)\NP 	 2 	 Warner-Lambert 's
7 	 2 	 (NP\NP)/NP 	 2 	 products of
7 	 4 	 (NP[nb]/N)\NP 	 1 	 products 's
7 	 5 	 N/N 	 1 	 products non-prescription
7 	 6 	 N/N 	 1 	 products health-care
7 	 10 	 (NP\NP)/NP 	 1 	 products as
10 	 9 	 (NP\NP)/(NP\NP) 	 2 	 as such
13 	 10 	 (NP\NP)/NP 	 2 	 tablets as
13 	 11 	 N/N 	 1 	 tablets Halls
13 	 12 	 N/N 	 1 	 tablets cough
16 	 10 	 (NP\NP)/NP 	 2 	 antacid as
16 	 15 	 N/N 	 1 	 antacid Rolaids
21 	 10 	 (NP\NP)/NP 	 2 	 lotion as
21 	 19 	 N/N 	 1 	 lotion Lubriderm
21 	 20 	 N/N 	 1 	 lotion skin
23 	 25 	 (S\NP)\(S\NP) 	 2 	 increased %
23 	 26 	 ((S\NP)\(S\NP))/NP 	 2 	 increased to
23 	 30 	 ((S\NP)\(S\NP))/NP 	 2 	 increased in
25 	 24 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 3
27 	 26 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
29 	 27 	 N/N[num] 	 1 	 million $
29 	 28 	 N/N 	 1 	 million 362
33 	 30 	 ((S\NP)\(S\NP))/NP 	 3 	 quarter in
33 	 31 	 NP[nb]/N 	 1 	 quarter the
33 	 32 	 N/N 	 1 	 quarter third
36 	 35 	 N/N 	 1 	 sales U.S.
36 	 37 	 S[dcl]\NP 	 1 	 sales rose
37 	 39 	 (S\NP)\(S\NP) 	 2 	 rose %
39 	 38 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 5
<\s>
<s id="wsj_2007.20"> 10
2 	 0 	 N/N 	 1 	 sales Confectionery
2 	 1 	 N/N 	 1 	 sales products
2 	 4 	 (S[dcl]\NP)/NP 	 1 	 sales had
4 	 3 	 (S\NP)/(S\NP) 	 2 	 had also
4 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 had in
6 	 4 	 (S[dcl]\NP)/NP 	 2 	 growth had
6 	 5 	 N/N 	 1 	 growth strong
9 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 quarter in
9 	 8 	 NP[nb]/N 	 1 	 quarter the
<\s>
<s id="wsj_2007.21"> 24
1 	 0 	 N/N 	 1 	 sales World-wide
1 	 2 	 (NP\NP)/NP 	 1 	 sales of
1 	 17 	 S[b]\NP 	 1 	 sales increased
4 	 2 	 (NP\NP)/NP 	 2 	 gum of
4 	 3 	 N/N 	 1 	 gum Trident
8 	 2 	 (NP\NP)/NP 	 2 	 mints of
8 	 6 	 N/N 	 1 	 mints Certs
8 	 7 	 N/N 	 1 	 mints breath
15 	 2 	 (NP\NP)/NP 	 2 	 mints of
15 	 11 	 N/N 	 1 	 mints Clorets
15 	 12 	 N/N 	 1 	 mints gum
15 	 14 	 N/N 	 1 	 mints breath
17 	 19 	 (S\NP)\(S\NP) 	 2 	 increased %
17 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 increased to
19 	 18 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 12
21 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
23 	 21 	 N/N[num] 	 1 	 million $
23 	 22 	 N/N 	 1 	 million 277
<\s>
<s id="wsj_2007.22"> 19
1 	 0 	 N/N 	 1 	 shares Warner-Lambert
1 	 2 	 (S[dcl]\NP)/PP 	 1 	 shares closed
2 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 closed up
2 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 closed in
2 	 18 	 (S\NP)\(S\NP) 	 2 	 closed yesterday
3 	 2 	 (S[dcl]\NP)/PP 	 2 	 at closed
4 	 3 	 PP/NP 	 1 	 $ at
4 	 6 	 (NP\NP)/N 	 1 	 $ a
5 	 4 	 N/N[num] 	 1 	 109.50 $
7 	 6 	 (NP\NP)/N 	 2 	 share a
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 $ up
11 	 10 	 N/N[num] 	 1 	 1.50 $
17 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 trading in
17 	 14 	 N/N 	 1 	 trading Big
17 	 15 	 N/N 	 1 	 trading Board
17 	 16 	 N/N 	 1 	 trading composite
<\s>
<s id="wsj_2007.23"> 4
3 	 0 	 N/N 	 1 	 Co Eli
3 	 1 	 N/N 	 1 	 Co Lilly
3 	 2 	 N/N 	 1 	 Co &
<\s>
<s id="wsj_2007.24"> 29
0 	 1 	 ((S[dcl]\NP)/PP)/NP 	 1 	 Lilly attributed
6 	 1 	 ((S[dcl]\NP)/PP)/NP 	 3 	 results attributed
6 	 2 	 N/N 	 1 	 results record
6 	 3 	 N/N 	 1 	 results third-quarter
6 	 5 	 N/N 	 1 	 results nine-month
7 	 1 	 ((S[dcl]\NP)/PP)/NP 	 2 	 to attributed
9 	 7 	 PP/NP 	 1 	 gains to
9 	 8 	 N/N 	 1 	 gains world-wide
9 	 10 	 (NP\NP)/NP 	 1 	 gains for
9 	 18 	 (NP\NP)/NP 	 1 	 gains despite
11 	 10 	 (NP\NP)/NP 	 2 	 pharmaceuticals for
14 	 10 	 (NP\NP)/NP 	 2 	 instruments for
14 	 13 	 N/N 	 1 	 instruments medical
17 	 10 	 (NP\NP)/NP 	 2 	 products for
17 	 16 	 N/N 	 1 	 products plant-science
21 	 18 	 (NP\NP)/NP 	 2 	 rates despite
21 	 19 	 N/N 	 1 	 rates poor
21 	 20 	 N/N 	 1 	 rates exchange
21 	 22 	 (NP\NP)/NP 	 1 	 rates for
21 	 25 	 (NP\NP)/(S[dcl]\NP) 	 1 	 rates that
21 	 26 	 (S[dcl]\NP)/NP 	 1 	 rates slowed <XB>
24 	 22 	 (NP\NP)/NP 	 2 	 dollar for
24 	 23 	 NP[nb]/N 	 1 	 dollar the
26 	 25 	 (NP\NP)/(S[dcl]\NP) 	 2 	 slowed that
27 	 26 	 (S[dcl]\NP)/NP 	 2 	 sales slowed
27 	 28 	 NP\NP 	 1 	 sales abroad
<\s>
<s id="wsj_2007.25"> 52
0 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Earnings continued
0 	 3 	 (S[b]\NP)/NP 	 1 	 Earnings pace <XB>
1 	 5 	 ((S\NP)\(S\NP))/PP 	 2 	 continued because
2 	 1 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to continued
3 	 2 	 (S[to]\NP)/(S[b]\NP) 	 2 	 pace to
4 	 3 	 (S[b]\NP)/NP 	 2 	 sales pace
6 	 5 	 ((S\NP)\(S\NP))/PP 	 3 	 of because
10 	 6 	 PP/NP 	 1 	 rate of
10 	 7 	 NP[nb]/N 	 1 	 rate a
10 	 8 	 N/N 	 1 	 rate lower
10 	 9 	 N/N 	 1 	 rate tax
12 	 6 	 PP/NP 	 1 	 profit of
12 	 13 	 (NP\NP)/NP 	 1 	 profit from
15 	 13 	 (NP\NP)/NP 	 2 	 renegotiation from
15 	 14 	 NP[nb]/N 	 1 	 renegotiation the
15 	 16 	 (NP\NP)/NP 	 1 	 renegotiation of
19 	 16 	 (NP\NP)/NP 	 2 	 instrument of
19 	 17 	 NP[nb]/N 	 1 	 instrument the
19 	 18 	 N/N 	 1 	 instrument debt
19 	 20 	 (S[pss]\NP)/PP 	 1 	 instrument received <XB>
20 	 24 	 ((S\NP)\(S\NP))/NP 	 2 	 received in
21 	 20 	 (S[pss]\NP)/PP 	 2 	 from received
23 	 21 	 PP/NP 	 1 	 Inc. from
23 	 22 	 N/N 	 1 	 Inc. Faberge
25 	 24 	 ((S\NP)\(S\NP))/NP 	 3 	 connection in
25 	 26 	 (NP\NP)/NP 	 1 	 connection with
27 	 28 	 (NP[nb]/N)\NP 	 2 	 Lilly 's
29 	 26 	 (NP\NP)/NP 	 2 	 sale with
29 	 28 	 (NP[nb]/N)\NP 	 1 	 sale 's
29 	 30 	 (NP\NP)/NP 	 1 	 sale of
29 	 34 	 (NP\NP)/NP 	 1 	 sale in
33 	 30 	 (NP\NP)/NP 	 2 	 Inc. of
33 	 31 	 N/N 	 1 	 Inc. Elizabeth
33 	 32 	 N/N 	 1 	 Inc. Arden
35 	 34 	 (NP\NP)/NP 	 2 	 1987 in
39 	 6 	 PP/NP 	 1 	 proceeds of
39 	 38 	 N/N 	 1 	 proceeds net
39 	 40 	 (NP\NP)/NP 	 1 	 proceeds from
42 	 40 	 (NP\NP)/NP 	 2 	 settlement from
42 	 41 	 NP[nb]/N 	 1 	 settlement the
42 	 43 	 (NP\NP)/NP 	 1 	 settlement of
42 	 46 	 (NP\NP)/NP 	 1 	 settlement at
45 	 43 	 (NP\NP)/NP 	 2 	 litigation of
45 	 44 	 N/N 	 1 	 litigation patent
47 	 48 	 (NP[nb]/N)\NP 	 2 	 Lilly 's
51 	 46 	 (NP\NP)/NP 	 2 	 unit at
51 	 48 	 (NP[nb]/N)\NP 	 1 	 unit 's
51 	 49 	 N/N 	 1 	 unit Hybritech
51 	 50 	 N/N 	 1 	 unit Inc.
<\s>
<s id="wsj_2007.26"> 20
1 	 0 	 N/N 	 1 	 sales Third-quarter
1 	 2 	 (NP\NP)/NP 	 1 	 sales of
1 	 9 	 S[dcl]\NP 	 1 	 sales rose
6 	 4 	 (N/N)/(N/N) 	 2 	 Ind. Indianapolis
8 	 2 	 (NP\NP)/NP 	 2 	 company of
8 	 3 	 NP[nb]/N 	 1 	 company the
8 	 6 	 N/N 	 1 	 company Ind.
9 	 11 	 (S\NP)\(S\NP) 	 2 	 rose %
9 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
9 	 16 	 ((S\NP)\(S\NP))/NP 	 2 	 rose from
11 	 10 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 11
13 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
15 	 13 	 N/N[num] 	 1 	 billion $
15 	 14 	 N/N 	 1 	 billion 1.045
17 	 16 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
19 	 17 	 N/N[num] 	 1 	 million $
19 	 18 	 N/N 	 1 	 million 940.6
<\s>
<s id="wsj_2007.27"> 16
1 	 0 	 N/N 	 1 	 sales Nine-month
1 	 2 	 S[dcl]\NP 	 1 	 sales grew
2 	 4 	 (S\NP)\(S\NP) 	 2 	 grew %
2 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 grew to
2 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 grew from
4 	 3 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 12
6 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
8 	 6 	 N/N[num] 	 1 	 billion $
8 	 7 	 N/N 	 1 	 billion 3.39
9 	 15 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))\NP 	 3 	 from earlier
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
12 	 10 	 N/N[num] 	 1 	 billion $
12 	 11 	 N/N 	 1 	 billion 3.03
14 	 13 	 NP[nb]/N 	 1 	 year a
14 	 15 	 (((S\NP)\(S\NP))\((S\NP)\(S\NP)))\NP 	 4 	 year earlier
<\s>
<s id="wsj_2007.28"> 10
0 	 1 	 (NP\NP)/NP 	 1 	 Sales of
0 	 7 	 (S[dcl]\NP)/NP 	 1 	 Sales led
2 	 1 	 (NP\NP)/NP 	 2 	 Prozac of
5 	 1 	 (NP\NP)/NP 	 2 	 anti-depressant of
5 	 4 	 NP[nb]/N 	 1 	 anti-depressant an
9 	 7 	 (S[dcl]\NP)/NP 	 2 	 increases led
9 	 8 	 N/N 	 1 	 increases drug-sales
<\s>
<s id="wsj_2007.29"> 32
1 	 0 	 N/N 	 1 	 sales Higher
1 	 2 	 (NP\NP)/NP 	 1 	 sales of
1 	 8 	 S[adj]\NP 	 1 	 sales more <XB>
1 	 10 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 sales offset
3 	 2 	 (NP\NP)/NP 	 2 	 pesticides of
7 	 2 	 (NP\NP)/NP 	 2 	 products of
7 	 5 	 N/N 	 1 	 products other
7 	 6 	 N/N 	 1 	 products plant-science
8 	 9 	 ((S\NP)/(S\NP))\(S[adj]\NP) 	 3 	 more than
10 	 9 	 ((S\NP)/(S\NP))\(S[adj]\NP) 	 2 	 offset than
10 	 31 	 (S[dcl]\S[dcl])\NP 	 1 	 offset said
13 	 10 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 decline offset
13 	 11 	 NP[nb]/N 	 1 	 decline a
13 	 12 	 N/N 	 1 	 decline slight
13 	 14 	 (NP\NP)/NP 	 1 	 decline in
13 	 21 	 (S[b]\NP)/NP 	 1 	 decline fuel <XB>
16 	 14 	 (NP\NP)/NP 	 2 	 sales in
16 	 15 	 NP[nb]/N 	 1 	 sales the
16 	 17 	 (NP\NP)/NP 	 1 	 sales of
19 	 17 	 (NP\NP)/NP 	 2 	 products of
19 	 18 	 N/N 	 1 	 products animal-health
20 	 10 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to offset
21 	 20 	 (S[to]\NP)/(S[b]\NP) 	 2 	 fuel to
23 	 21 	 (S[b]\NP)/NP 	 2 	 increase fuel
23 	 22 	 NP[nb]/N 	 1 	 increase the
23 	 24 	 (NP\NP)/NP 	 1 	 increase in
28 	 24 	 (NP\NP)/NP 	 2 	 sales in
28 	 25 	 N/N 	 1 	 sales world-wide
28 	 26 	 N/N 	 1 	 sales agricultural
28 	 27 	 N/N 	 1 	 sales product
30 	 31 	 (S[dcl]\S[dcl])\NP 	 2 	 Lilly said
<\s>
<s id="wsj_2007.30"> 16
3 	 0 	 N/N 	 1 	 Inc. Advanced
3 	 1 	 N/N 	 1 	 Inc. Cardiovascular
3 	 2 	 N/N 	 1 	 Inc. Systems
3 	 9 	 (S[dcl]\NP)/NP 	 1 	 Inc. led
8 	 5 	 N/N 	 1 	 units Cardiac
8 	 6 	 N/N 	 1 	 units Pacemakers
8 	 7 	 N/N 	 1 	 units Inc.
8 	 9 	 (S[dcl]\NP)/NP 	 1 	 units led
10 	 9 	 (S[dcl]\NP)/NP 	 2 	 growth led
10 	 11 	 (NP\NP)/NP 	 1 	 growth in
15 	 11 	 (NP\NP)/NP 	 2 	 division in
15 	 12 	 NP[nb]/N 	 1 	 division the
15 	 13 	 N/N 	 1 	 division medical-instrument
15 	 14 	 N/N 	 1 	 division systems
<\s>
<s id="wsj_2007.31"> 18
1 	 0 	 N/N 	 1 	 shares Lilly
1 	 2 	 (S[dcl]\NP)/PP 	 1 	 shares closed
2 	 3 	 (S\NP)\(S\NP) 	 2 	 closed yesterday
2 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 closed in
2 	 15 	 ((S\NP)\(S\NP))/NP 	 2 	 closed down
6 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 trading in
6 	 5 	 N/N 	 1 	 trading composite
6 	 7 	 (NP\NP)/NP 	 1 	 trading on
10 	 7 	 (NP\NP)/NP 	 2 	 Board on
10 	 8 	 NP[nb]/N 	 1 	 Board the
10 	 9 	 N/N 	 1 	 Board Big
11 	 2 	 (S[dcl]\NP)/PP 	 2 	 at closed
12 	 11 	 PP/NP 	 1 	 $ at
13 	 12 	 N/N[num] 	 1 	 62.25 $
17 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 cents down
17 	 16 	 N/N 	 1 	 cents 12.5
<\s>
